LivaNova (NASDAQ:LIVN) Downgraded to Buy Rating by StockNews.com

LivaNova (NASDAQ:LIVN) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

LIVN has been the subject of several other research reports. Mizuho decreased their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Stifel Nicolaus lifted their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group started coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $52.10 on Friday. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $64.47. The business has a 50 day moving average price of $51.67 and a two-hundred day moving average price of $52.98. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.83 billion, a PE ratio of 124.05 and a beta of 1.01.

Institutional Trading of LivaNova

Several hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in shares of LivaNova in the 3rd quarter worth approximately $550,000. Point72 DIFC Ltd lifted its holdings in shares of LivaNova by 75,799.6% in the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock worth $9,531,000 after purchasing an additional 181,161 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Polar Asset Management Partners Inc. bought a new stake in shares of LivaNova in the 3rd quarter worth approximately $1,949,000. Finally, Parkman Healthcare Partners LLC raised its stake in LivaNova by 19.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 101,729 shares of the company’s stock valued at $5,345,000 after acquiring an additional 16,570 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.